CD177 and cancer: Instead, combination therapy of substances that address multiple pathways simultaneously, for example inhibitors of cell-surface receptors (Imatinib [12], RAP [13, 28], Icatibant [44]) together with plasma and intracellular enzymes antagonists (GM6001 [20], BPCCB [11] and fasudil/KD025 [30, 46], respectively) should be considered, similar to growing approaches in cancer therapy.